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The development of type 1 diabetes (T1D) is driven by autoreactive T cells that attack
and destroy the insulin-producing β-cells in pancreatic islets, forcing patients to take mul-
tiple daily insulin injections. Insulin therapy, however, is not a cure and diabetic patients
often develop serious long-termmicrovascular and cardiovascular complications.Therefore,
intensive efforts are being directed toward developing safe immunotherapy for the disease
that does not impair host defense and preserves β-cells, leading to better glycemic control
than exogenous insulin therapy. Engineering therapies that differentially cripple or tolerate
autoreactive diabetogenicT cells while sparing protectiveT cells necessary for maintaining
a competent immune system has proven challenging. Instead, recent efforts have focused
on modulating or resetting the immune system through global but transient deletion of
T cells or B cells using anti-CD3 or anti-CD20 mAb, respectively. However, phase III clinical
trials have shown promising but modest efﬁcacy so far with these approaches. Therefore,
there is a need to identify novel biological targets that do not ﬁt the classic properties of
being involved in adaptive immune cell activation. In this prospective, we provide preclinical
evidence that targeting Fas ligand (FasL) may provide a unique opportunity to prevent or
cureT1D and perhaps other organ-speciﬁc autoimmune diseases without causing immune
suppression. Unlike conventional targets that are involved in T and B lymphocyte activa-
tion (such as CD3 and CD20, respectively), FasL is an apoptosis-inducing surface molecule
that triggers cell death by binding to Fas (also known as CD95 Apo-1). Therefore, target-
ing FasL is not expected to cause immune suppression, the Achilles Heel of conventional
approaches. We will discuss the hypothesis that targeting FasL has unique beneﬁts that
are not offered by current immunomodulatory approaches.
Keywords: autoimmune diabetes, Fas pathway, immunotherapy, immunosuppression, apoptosis, lymphoprolifer-
ative disorders
INTRODUCTION
Autoimmune diabetes, also known as type 1 diabetes (T1D), is a
common chronic disease that strikes predominantly in childhood,
adolescence or early adulthood and persists lifelong (Bluestone
et al., 2010). It is clinically characterized by hyperglycemia due
to the destruction of insulin-producing β-cells by diabetogenic
T cells. Prior to the use of insulin for the management of T1D
in 1922, T1D was invariably a fatal disease (Joslin, 1924, 1936).
Since then, signiﬁcant progress has been made in the develop-
ment of long and short acting insulin analog regimens, home
glucometers, continuous glucose sensors, and insulin pumps.
Despite these advances, tight glycemic control remains an elu-
sive and overwhelming challenge, requiring constant attention
to blood glucose levels and carbohydrate intake (Patterson et al.,
2009; Dahlquist et al., 2011; Harjutsalo et al., 2011). Patients
continue to suffer from long-term diabetes complications includ-
ing cardiovascular disease, chronic kidney disease, retinopathy
which can progress to blindness, and peripheral neuropathy
(Bluestone et al., 2010). Patients are also faced with the potential
for life threatening episodes of diabetic ketoacidosis or hypo-
glycemia. T1D incidence has been steadily rising in young children
for unclear reasons (Patterson et al., 2009; Dahlquist et al., 2011;
Harjutsalo et al., 2011). Therefore, the need to develop a cure or
preventive therapy for T1D is great. While a cure is deﬁned as
the lack of the need for exogenous insulin, developing a therapy
that simply decreases the need for intensive insulin management
and improve glycemic control would be transformative. Patients
intensively treated with insulin in the Diabetes Control and Com-
plications Trial (DCCT), who had higher baseline C-peptide
concentrations (≥0.20 pmol/ml) indicating greater endogenous
insulin secretion, on follow-up, had lower hemoglobin A1c lev-
els, and a reduced risk for developing diabetic complications
and severe hypoglycemia. Interventions which preserve endoge-
nous insulin secretion may therefore improve control and prevent
complications in patients with T1D (The Diabetes Control and
Complications Trial Research Group, 1998).
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THE CHALLENGE TO DEVELOPING EFFECTIVE
IMMUNOTHERAPY FOR T1D
Despite the daily burden of monitoring blood sugar, taking
insulin, and experiencing episodic and occasionally severe hypo-
glycemia, T1D patients can enjoy a relatively healthy life for
decades. Consequently, the safety standards for immunotherapeu-
tic intervention for T1D are high. The risk/beneﬁt balance must
clearly exceed that of insulin analog therapy for such interventions
to be widely acceptable. The main serious risk associated with
most current immunotherapeutic approaches is that of immuno-
suppression. Avoiding immunosuppression is a major challenge
given that diabetogenic T cells in reality are “misguided” effector
T cells that direct their destructive power against islet autoantigens
instead of foreign pathogens. Major islet autoantigens are derived
from insulin, glutamic acid decarboxylase (GAD65), insulinoma-
associated antibody 2 (IA-2), and zinc transporter 8 (ZnT8)
proteins (Nakayama et al., 2005;Wenzlau et al., 2009). Recognition
of these autoantigens, primarily insulin peptide, by diabeto-
genic T cells initiates the autoimmune response that leads to
the ultimate destruction of insulin-producing β-cells and hyper-
glycemia (Figure 1). In the process, diabetogenic T cells utilize
the same recognition systems and costimulatory pathways as do
effector T cells speciﬁc for invading pathogens. These common
systems and pathways regulate T cell proliferation, differentia-
tion, cytokine secretion, and homing to the site of action whether
it is an autoimmune target organ or an infected tissue. There-
fore, non-speciﬁc targeting of a vast array of molecules that
cripple islet reactive T cells and prevents autoimmunity can also
FIGURE 1 | Key events inT1D development. (I) The process starts by
acquisition and delivery of islet autoantigens including insulin and GAD65
proteins by antigen presenting cells (APCs) to the draining, pancreatic
lymph nodes (PLNs). (II) Diabetogenic T cells encounter their cognate
autoantigens presented by APCs in PLNs leading to their priming,
proliferation and differentiation into effector T cells, and homing functions
as a result of interaction with APCs. (III) Diabetogenic effector T cells
migrate into the pancreas and inﬁltrate pancreatic islets causing insulitis
and eventually destruction of insulin-producing β-cells.
impair protective T cell function thereby impinging on the host’s
ability to mount effective immune responses against invading
pathogens. An ideal immunotherapeutic approach would be a
one that induces immunologic tolerance to islet autoantigens in
high risk individuals and new-onset T1D patients without caus-
ing long-term immune suppression. Hypothetically, this can be
achieved by developing strategies to selectively eliminate and/or
immunoregulate diabetogenic T cells without disrupting nor-
mal immune homeostasis or host defense. Despite remarkable
achievements in our understanding of basic immunology and
disease processes, to date no mechanisms have been identiﬁed
that selectively inhibit activation of autoreactive T cells without
impairing responsiveness of protective T cells. This dilemma has
greatly impededprogress indeveloping successful immunotherapy
for T1D.
In the presumed absence of immunologic targets that can be
safely targeted to prevent autoimmunity without comprising host
defense, some creative approaches have been developed to min-
imize side effects of targeting molecules by modulating/resetting
the immune system through global but transient deletion of T cells
or B cells using anti-CD3 or anti-CD20 mAb, respectively. In spite
of some early successes in phase I and II clinical trials (Bolt et al.,
1993; Herold et al., 2005; van Belle et al., 2011), different anti-CD3
mAbs (Otelixizumab, Teplizumab) failed to meet primary efﬁcacy
endpoints in recent phase III clinical trials to impact primary out-
comes including hemoglobin A1c (HbA1C), insulin requirements
or C-peptide values. A higher dose of the humanized CD3-
antibody, ChAglyCD3 (Otelixizumab) led to a decline in insulin
requirements after 4 yearswhen comparedwith placebo treatment.
However, the higher dose was associated with signiﬁcant cytokine
release symptoms on infusion days, and led to reactivation of
Epstein Barr virus infection (Keymeulen et al., 2010). In the Pro-
tégé Study, new-onset T1D subjects who received the highest dose
of teplizumab had less decline in C-peptide secretion when com-
pared with placebo, allowing glycemic control to be achieved at a
lower insulin dose, indicating a partial therapeutic effect (Sherry
et al., 2011). Anti-CD20 antibody is another potential T1D ther-
apy under investigation. CD20 is expressed on the surface of all
B cells except plasma cells. Clinical trials with the anti-CD20 mAb
Rituximab yielded some degree of success as it helped to preserve
residual insulin production in new-onset T1D patients, reduced
insulin requirements, and lowered autoantibody levels and HbA1c
(Pescovitz et al.,2009;Yu et al.,2011). Therewere, however, adverse
effects including long-term depressed IgM levels, which increases
the risk of immunosuppression. Moreover, patients receiving the
drug reported a range of side effects including fever, rash, nausea,
hypotension, and tachycardia. These studies show that current
T cell and B cell antibodies have signiﬁcant adverse effects, and at
best incompletely prevent progressive β-cell loss. They therefore
call into question the utility and effectiveness of anti-CD3 or anti-
CD20 as stand alone immunotherapies to preserve β-cell function
(Sherry et al., 2011; and unpublished data presented at the Ameri-
can Diabetes Association Annual Meeting, San Diego, CA, USA in
June 2011).
One promising approach still in its infancy is to utilize Treg
cells to selectively inhibit autoreactive T cells. This approach has
been challenged by the inability to selectively expand andmaintain
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Treg cells, as reduced frequency or function of Treg cells, or
both, is believed to underlie autoimmune diabetes (Atkinson et al.,
2011) and other immune-mediated diseases (Koreth et al., 2011;
Saadoun et al., 2011). However, recent studies have shown that
low doses of IL-2 can be used to promote survival of Treg cells in
the non-obese diabetic (NOD) mouse model (Tang et al., 2008)
and even to reverse new-onset diabetes (Grinberg-Bleyer et al.,
2010). In a clinical trial of IL-2 and Sirolimus in autoimmune
diabetes (Proleukin and Rapamune in Type 1 diabetes; Clini-
calTrials.gov number, NCT00525889), natural killer-cell count
increased and may have been responsible for transient decrease
in the function of β-cells. Nonetheless, low dose of IL-2 ther-
apy has been shown to preferentially induce Treg expansion and
lead to reversing of immune-mediated human diseases (Koreth
et al., 2011; Saadoun et al., 2011), whereas a high dose treat-
ment results in a relative increase in effector T cells population
(Bluestone, 2011).
An approach we are advocating is to target the Fas pathway, the
prototypical extrinsic death pathway that regulates T cell home-
ostasis (Nagata and Golstein, 1995). In this perspective, we will
discuss the potential of targeting Fas ligand (FasL) as a novel
approach to prevent autoimmune destruction of β-cells that is
strongly merited by recent ﬁndings in the NOD mouse.
THE Fas PATHWAY: A POTENTIAL THERAPEUTIC
TARGET FOR T1D
It has long been known that the Fas pathway plays an important
role in maintaining homeostasis of the immune system. Pioneer-
ing studies by Nagata and Golstein (1995) have established the Fas
pathway as the prototypical extrinsic death pathway. FasL, a tumor
necrosis factor-related type II transmembrane protein, initiates
an apoptosis signaling cascade by binding to Fas (also known as
CD95 or Apo-I) on the target cell triggering cell death (Figure 2).
Fas/FasL interaction leads to the formation of death-inducing sig-
naling complex (DISC) that includes Fas-associated protein with
death domain (FADD) and aspartate-speciﬁc cysteine protease,
caspase-8 (Nagata and Golstein, 1995). FADD-mediates activa-
tion of the proteolytic activity of caspase 8, which is essential
for Fas-induced apoptosis (Denault and Salvesen, 2002). Active
caspase-8 leaves the DISC and proteolytically activates down-
stream effector caspases such as caspase-3 and caspase-7 that
perform the bulk of the proteolysis of vital cellular proteins
and cleavage of internucleosomal DNA, a hallmark of apoptosis
(Lenardo, 1996).
At the cellular level, death of TCR activated hybridomas and
primary T cells upon Fas/FasL interactions in vitro led to estab-
lishment of the paradigm that Fas-mediated activation-induced
cell death (AICD) is a major negative regulator of T cell clonal
expansion (Brunner et al., 1995; Dhein et al., 1995; Ju et al., 1995).
The discovery that T cell lymphoproliferation in lpr and gldmice is
due to pointmutations in Fas and FasL, respectively, conﬁrmed the
physiologic role of the Fas pathway in regulating T cell homeosta-
sis (Nagata and Suda, 1995). Nevertheless, the biological context
in which the Fas pathway regulates T cell homeostasis in vivo
remains unclear. The basis of the unusual composition of T cells
that cause lymphoproliferation in mice bearing homozygous lpr
or gld mutations is poorly understood. The lymphoproliferation
FIGURE 2 | FasL interaction with its receptor (Fas) triggers cell death.
Binding of FasL to Fas induces the apoptosis of Fas-bearing cells by
activation of the caspase signaling cascade leading to cleavage of nuclear
DNA and proteolysis of vital cellular proteins.
is predominantly caused by a subset of double negative αβ T cells
(hereafter referred to as DN T cells) that lack both CD4 and CD8
coreceptors and that is a rare component of the normal T cell
population in the secondary lymphoid organs. Thymic negative
selection proceeds normally in mutant mice ruling out defective T
cell development as a major cause of lymphoproliferation (Kotzin
et al., 1988; Singer et al., 1989; Mountz et al., 1990; Zhou et al.,
1992). Furthermore, whereas some early studies indicated a delay
or defect in deletion of Fas-deﬁcient T cells in response to stim-
ulation by foreign antigens (Gillette-Ferguson and Sidman, 1994;
Mogil et al., 1995), recent studies reported minor or no disrup-
tion of effector T cell clearance in mice with impaired Fas pathway
(Gonzalo et al., 1994; Lohman et al., 1996; Miethke et al., 1996;
Hildeman et al., 2002). Consistently, humans and mice with defec-
tive Fas pathway efﬁciently show no defects in clearance of excess
effector T cells following acute immune responses (Strasser et al.,
2009). Indeed, it is becoming increasingly clear that the proapop-
totic molecule Bim (BCL-2 interacting mediator of cell death) is
the major regulator of foreign antigen-activated T cell apoptosis
in vivo (Bouillet and O’Reilly, 2009). Furthermore, because the
Fas pathway mainly regulates apoptosis, mice with impaired Fas
pathway show no defect in clearing viral infections and remain
immunocompetent (Watanabe-Fukunaga et al., 1992; Hildeman
et al., 2002; Hamad, 2010). Thus, immune responses to acute
infections appear to proceed remarkably normal in the absence
www.frontiersin.org July 2012 | Volume 3 | Article 196 | 3
“ﬁmmu-03-00196” — 2012/7/12 — 12:23 — page 4 — #4
Hamad et al. FasL: a counterintuitive immunotherapeutic target
of functional Fas pathway. However, deletion of chronically acti-
vated T cells due to infections with persistent pathogens appears
to be impaired in mutant mice (Stranges et al., 2007; Bouillet and
O’Reilly, 2009). In addition, chronic activation by self antigens
may be a factor in drivingDNTcell accumulation even in germfree
(GF) mice, suggesting no major role for microbiota in the process
(Maldonado et al., 1999).
Early historic rise and fall of interest in the Fas pathway as an
immunomodulator of T1D.
The discovery in the early 1990s of the loss-of-function muta-
tions in Fas (called the lpr mutation) and FasL (called the gld
mutation) enabled the assessment of Fas and FasL on the diabeto-
genic process in the widely used NOD mice (Nagata and Suda,
1995). The initial ﬁnding that NOD mice bearing homozygous lpr
or gld mutations are completely protected from autoimmune dia-
betes (Chervonsky et al., 1997; Su et al., 2000; Petrovsky et al., 2002;
Mohamood et al., 2007) unveiled the pivotal role for the Fas path-
way in driving the pathogenic process of autoimmune diabetes
and led to great excitement in the therapeutic potential of target-
ing the Fas pathway. Based on the physiological role of Fas/FasL
interaction in mediating cell death and that TCR activation leads
to FasL upregulation, it was presumed that FasL expressed on
inﬁltrating T cells engages Fas on the surface of β-cells leading to
their apoptosis (Chervonsky et al., 1997). This hypothesis, how-
ever, did not materialize because speciﬁc deletion of the Fas gene
in β-cells did not spare them from autoimmune destruction (Kim
et al., 1999; Apostolou et al., 2003). The dispensable role of Fas-
mediated apoptosis in destroying β-cells was disappointing and
puzzling at the same time, as it became difﬁcult to fathom an alter-
native mechanism to explain this potent phenomenon. Thereafter,
the view that the protective effect of inactivating the Fas pathway
on autoimmune diabetes is an epiphenomenon prevailed. This
view is enforced by the fact that mice bearing homozygous gld
or lpr mutation develop an age-dependent lymphoproliferation
that is predominated by double negative αβ T cells that are rare in
normal mice (Watanabe-Fukunaga et al., 1992).
The complete protection from insulitis by the gld and lpr
mutations in autoimmune diabetes prone NOD mice occurs
even though mutant mice develop age-dependent though benign
T cell lymphoproliferation. The absence of insulitis and overt
diabetes in the presence of large numbers of activated T cells
underlies the potency of the protective mechanism(s). Yet the
lymphoproliferation is an obviously unwelcome side effect that is
commonly associated with the development of anti-nuclear anti-
bodies and lupus-like condition whose severity depends on the
genetic background of the mouse strain (Cohen and Eisenberg,
1991). The lymphoproliferation has also frustrated the efforts to
investigate and uncover mechanisms by which inactivation of the
Fas pathway prevents autoimmune diabetes. As a consequence,
the belief that protection from diabetes is an epiphenomenon
related to the distortion of the immune system by expansion
of DN T cells passed unchallenged and interest in pursuing the
Fas pathway as a therapeutic target faded. However, the protec-
tive effect of inactivating the Fas pathway has also been seen in
other models of organ-speciﬁc autoimmune diseases, including
multiple sclerosis, and inﬂammatory conditions (Waldner et al.,
1997; Henriques-Pons and de Oliveira, 2009; Ko et al., 2011).
Nevertheless, the question of whether the protective effects and
lymphoproliferation are consequential or dissociable side effects of
inactivating the Fas pathway has remained unanswered for a long
period of time.
Why revisit the potential of FasL as a therapeutic target in T1D?
During the past few years, we have developed encouraging evi-
dence from investigating disease resistance of NOD-gld/+ mice
(Figure 3) and prevention of diabetes development in NOD-wt
mice using a FasL-neutralizing mAb (Figure 4). These studies
have shown that the protective effect of targeting FasL is dis-
sociable from the lymphoproliferation: heterozygous gld NOD
mice are completely protected from autoimmune diabetes, yet
do not develop lymphoproliferation (Su et al., 2000; Nakayama
et al., 2002; Mohamood et al., 2007). The translational evidence
is the most exciting, as blockade of FasL with MFL4-neutralizing
mAb prevents the disease in wild type NOD mice without caus-
ing lymphoproliferation (Nakayama et al., 2002; Mohamood et al.,
2007). These results indicate that, contrary to the previously
long held belief, FasL may be worth dedicated investigation as
a therapeutic target. There are unique advantages for target-
ing FasL that are associated with the following properties of the
Fas pathway:
Fas/FasL INTERACTION IS NOT REQUIRED FOR T CELL ACTIVATION
As postulated by the widely accepted two signals model for T
cell stimulation, optimal activation requires one signal to be
delivered by the T cell receptor (TCR) engagement of cognate
MHC–peptide complex and a second signal provided by the
costimulatory molecule CD28 binding to CD80 and CD86
molecules on antigen presenting cells (APCs). Although previous
evidence indicated that FasL can costimulate TCR transgenic CD8
T cell proliferation in an adoptive transfer system (Suzuki et al.,
2000), the magnitude and potency of normal T cells is largely
unaffected and in some circumstances enhanced by the absence of
FasL (Hildeman et al., 2002; Mohamood et al., 2008). Therefore,
targeting FasL is not expected to negatively impact T cell activation
as shown by efﬁcient clearance of acute viral infections by Fas and
FasL-deﬁcient mutant mice (Hughes et al., 2008; Hutcheson et al.,
2008; Weant et al., 2008).
Fas/FasL INTERACTION IS NOT REQUIRED FOR DELETION
OF EFFECTOR T CELLS GENERATED IN THE ACUTE,
NORMAL ADAPTIVE IMMUNE RESPONSE
WhenT cells respond to acute antigenic stimulation in vivo follow-
ing infection, they become activated, proliferate and differentiate
into effector cells that clear the invading pathogen (Marrack and
Kappler,2004). Once thepathogen is cleared,most of the effectorT
cells are deleted and immunehomeostasis is restored. Interestingly,
the Fas pathway plays a minor or no role in the deletion of effector
T cells generated in response to acute infections. Such effector T
cells are normally deleted by the intrinsic death pathway,mainly by
the BH3-only Bcl-2 family member Bim (Hildeman et al., 2002).
In contrast, the Fas pathway is required for deletion of chroni-
cally activated T cells, and most recent evidence from our group
indicates that Fas-mediated apoptosis is involved with restricting
DNT cells to the epithelial space (Hamad, 2010). Therefore, down-
modulating FasL activity is expected to impose little impact on the
Frontiers in Immunology | Immunological Tolerance July 2012 | Volume 3 | Article 196 | 4
“ﬁmmu-03-00196” — 2012/7/12 — 12:23 — page 5 — #5
Hamad et al. FasL: a counterintuitive immunotherapeutic target
FIGURE 3 | Single gld allele provides complete protection from
diabetes without causing lymphoproliferation. (A) Images of spleens
and peripheral lymph nodes of NOD mice bearing homozygous (gld/gld),
heterozygous (gld/+) mutation or wt (WT) FasL. (B) Homozygous and
heterozygous gld mutations completely prevent diabetes in NOD mice
as compared to NOD-wt littermates. NOD mice bearing homozygous gld
mutations develop an age-dependent lymphoproliferation (A) and become
completely protected from diabetes (B). NOD mice bearing the heterozygous
gld mutation develop no lymphoproliferation but become completely
protected from autoimmune diabetes (B). Wild type NOD mice develop
no lymphoproliferation but develop autoimmune diabetes (adapted from
Mohamood et al., 2007).
FIGURE 4 | Anti-FasL treatment protects against diabetes development.
Four-week-old NOD-wt mice were injected weekly, i.p. with 500 μg of
anti-FasL MFL4 antibody (n = 10) or control hamster IgG (n = 9) for two
consecutive weeks followed by 300 μg weekly injections until the age of 16
weeks. (A) Diabetes incidence in the two groups. (B) Anti-FasL treatment
curtails insulitis development in NOD-wt mice. Pancreata from three mice in
the anti-FasL group or from three non-diabetic mice in the control group were
collected 9 weeks after termination of the treatment and analyzed for insulitis.
Representative H&E sections show no insulitis (top, left) or peri-insulitis (top,
right) in islets of mice that received anti-FasL and severe insulitis in islets of
mice in the control group (left, bottom). The histogram shows percent of
islets with insulitis (ﬁlled bars), peri-insulitis (shaded bars) or no insulitis
(open bar) in anti-FasL (120 islets) and control (42 islets) groups.
(C)Treatment led to an only mild and transient increase in DNT cells. PBL
were stained and the frequency of TCR+CD4−CD8− (DN) cells relative to
total T cells was determined. Results are expressed as mean ± SEM. (D)
Anti-FasL treated NOD-wt mice were grafted with syngeneic skins (left) or
allogeneic (right) skin grafts from C3H mice 15 weeks after the last injection.
The allograft skins were rejected within 7 days (3/3). Data adapted from
Mohamood et al. (2007).
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expansion and contraction of T cells in response to acute infection.
In addition, as discussed below, our mouse studies indicate a wide
window for downregulating FasL activity to prevent autoimmune
diabetes without perturbing immune homeostasis (Su et al., 2000;
Mohamood et al., 2007).
A WIDE THERAPEUTIC WINDOW EXISTS TO DOWN MODULATE
FasL ACTIVITY TO PREVENT T1D WITHOUT CAUSING
LYMPHOPROLIFERATION
Because FasL functions as a homotrimer that is generated by ran-
dom pre-association of single chains, expression of one gld allele
in NOD hosts (NOD-gld/+) causes FasL haploinsufﬁciency due
to incorporation of at least one gld mutation in about 85% of
FasL homotrimers, thereby impairing their ability to bind Fas
receptor (Siegel et al., 2000). The effect of FasL on immune home-
ostasis, the primary physiologic function of the Fas pathway, is
negligible as NOD-gld/+ mice maintain normal immune home-
ostasis with no signs of lymphoproliferation (Mohamood et al.,
2007). Nonetheless, as shown in Figure 3, FasL haploinsufﬁ-
ciency completely protects NOD-gld/+ mice from developing
autoimmune diabetes (Mohamood et al., 2007). Based on these
results, we postulate that completely functional FasL is required
for driving the autoimmune process whereas only residual FasL
function is sufﬁcient for maintaining immune homeostasis (it
is estimated that only about 15% of FasL homotrimers are
functional in NOD-gld/+ mice yet there are no proliferation
or ANA production). The ability of FasL-neutralizing mAb to
prevent diabetes development in NOD-wt mice without caus-
ing lymphoproliferation or autoantibody production (Su et al.,
2000; Nakayama et al., 2002; Mohamood et al., 2007; Figure 4)
is consistent with the existence of a large functional window
to safely downregulate FasL activity for therapeutic purposes.
Thus, FasL activity can potentially be targeted to induce organ-
speciﬁc immunotolerance. This notion may not be limited to
autoimmune diabetes as the Fas pathway inactivation also pre-
vents experimental autoimmune encephalomyelitis (EAE), the
animal model of multiple sclerosis (Waldner et al., 1997). These
new approaches offer breakthrough models to investigate the role
of the Fas pathway in autoimmune diabetes that can potentially
lead to a novel therapeutic strategy that does not directly target
T cells.
CONCLUSION
Recent data provide proof-of-concept that antibody blockade
against FasL can speciﬁcally and signiﬁcantly arrest T1D devel-
opment in vivo (Mohamood et al., 2007; Su et al., 2007). The
safety concerns and adverse side effects of antigen non-speciﬁc
interventions, as well as the lack of permanent remission of dis-
ease with any agent tested to date, have heightened interest in
identifying non-conventional strategies to modulate the disease.
The unique property of FasL as an apoptosis-inducing molecule
makes it a potentially attractive target as standalone therapy or a
component of complementary immunotherapeutic strategies for
autoimmune diseases. Additional research is needed to further
investigate this pathway and understanding its speciﬁc mechanis-
tic roles in driving development of T1D. It will be particularly
interesting to determine whether Fas-mediated apoptosis is medi-
ating cytotoxicity of diabetogenic CD8 T cells, which has recently
been implicated in killing β-cells in T1D patients (Bulek et al.,
2012; Coppieters et al., 2012) or involved in killing regulatory cells
responsible for protecting the pancreas from autoreactive T cells.
It is our goal and expectation that this perspective will provoke
novel research that will unravel the important, yet complex, role
of the Fas signaling pathway in regulating autoimmune diabetes
and other organ-speciﬁc autoimmune diseases.
ACKNOWLEDGMENTS
The work was supported by the Peter and Teresa Nicholl Dia-
betes Research Fund and by grants from American Heart Asso-
ciation (10GRNT4200003), Juvenile Diabetes Research Fund
(JDRF-5-2010-627), and the National Institute of Public Health
(1R56AI099027-01). The artwork in Figure 1 and 2 is per-
formed by Catherine E. Kiefe from Medical Art at Johns Hopkins
University.
REFERENCES
Apostolou, I., Hao, Z., Rajewsky,
K., and von Boehmer, H. (2003).
Effective destruction of Fas-deﬁcient
insulin-producing beta cells in type
1 diabetes. J. Exp. Med. 198,
1103–1106.
Atkinson, M. A., Bluestone, J. A., Eisen-
barth, G. S., Hebrok, M., Herold, K.
C., Accili, D., Pietropaolo, M., Arvan,
P. R., Von Herrath, M., Markel, D. S.,
and Rhodes, C. J. (2011). How does
type 1 diabetes develop?: the notion
of homicide or beta-cell suicide revis-
ited. Diabetes 60, 1370–1379.
Bluestone, J. A. (2011). The yin
and yang of interleukin-2-mediated
immunotherapy. N. Engl. J.Med. 365,
2129–2131.
Bluestone, J. A., Herold, K., and Eisen-
barth, G. (2010). Genetics, pathogen-
esis and clinical interventions in type
1 diabetes. Nature 464, 1293–1300.
Bolt, S., Routledge, E., Lloyd, I., Chate-
noud, L., Pope, H., Gorman, S.
D., Clark, M., and Waldmann, H.
(1993). The generation of a human-
ized, non-mitogenic CD3 mono-
clonal antibody which retains in vitro
immunosuppressive properties. Eur.
J. Immunol. 23, 403–411.
Bouillet, P., and O’Reilly, L. A. (2009).
CD95, BIM and T cell homeostasis.
Nat. Rev. Immunol. 9, 514–519.
Brunner, T., Mog, R., LaFace, D.,
Yoo, N., Mahboubl, A., Echeverri,
F., Martin, S., Force, W., Lynch,
D., Ware, C., and Green, D. (1995).
Cell autonomous Fas (CD95)/Fas lig-
and interaction mediates activation
induced apoptosis in T cell hybrido-
mas. Nature 373, 441–444.
Bulek, A. M., Cole, D. K., Skowera,
A., Dolton, G., Gras, S., Madura, F.,
Fuller, A., Miles, J. J., Gostick, E.,
Price, D. A., Drijfhout, J. W., Knight,
R. R., Huang, G. C., Lissin, N., Mol-
loy, P. E., Wooldridge, L., Jakobsen,
B. K., Rossjohn, J., Peakman, M.,
Rizkallah, P. J., and Sewell, A. K.
(2012). Structural basis for the killing
of humanbeta cells byCD8(+)T cells
in type 1 diabetes. Nat. Immunol. 13,
283–289.
Chervonsky, A. V., Wang, Y., Wong, F.
S., Visintin, I., Flavell, R. A., Janeway,
C. A. Jr., and Matis, L. A. (1997). The
role of Fas in autoimmune diabetes.
Cell 89, 17–24.
Cohen, P., and Eisenberg, R. (1991).
Lpr and gld: single gene models
of systemic autoimmunity and lym-
phoproliferative disease. Annu. Rev.
Immunol. 9, 243–269.
Coppieters, K. T., Dotta, F., Amirian, N.,
Campbell, P. D., Kay, T. W., Atkinson,
M. A., Roep, B. O., and von Her-
rath, M. G. (2012). Demonstration
of islet-autoreactive CD8 T cells in
insulitic lesions fromrecent onset and
long-term type 1 diabetes patients. J.
Exp. Med. 209, 51–60.
Dahlquist, G. G., Nystrom, L., and Pat-
terson, C. C. (2011). Incidence of
type 1 diabetes in Sweden among
individuals aged 0–34 years, 1983–
2007: an analysis of time trends.
Diabetes Care 34, 1754–1759.
Denault, J. B., and Salvesen,G. S. (2002).
Caspases. Curr. Protoc. Protein Sci.
Chapter 21, Unit 21 28.
Dhein, J., Walczack, H., Baumler, C.,
Debatin, K.-M., and Krammer, P.
(1995). AutocrineT cell suicidemedi-
ated by APO-1 (Fas/CD95). Nature
373, 438–441.
Gillette-Ferguson, I., and Sidman, C. L.
(1994). A speciﬁc intercellular path-
wayof apoptotic cell death is defective
in the mature peripheral T cells of
autoimmune lpr and gld mice. Eur.
J. Immunol. 24, 1181–1185.
Frontiers in Immunology | Immunological Tolerance July 2012 | Volume 3 | Article 196 | 6
“ﬁmmu-03-00196” — 2012/7/12 — 12:23 — page 7 — #7
Hamad et al. FasL: a counterintuitive immunotherapeutic target
Gonzalo, J. A., Tarazona, R., Schu-
urman, H. J., Uytdehaag, F., Wick,
G., Martinez, C., and Kroemer,
G. (1994). A single injection of
Staphylococcus aureus enterotoxin B
reduces autoimmunity in MRL/lpr
mice. Clin. Immunol. Immunopathol.
71, 176–182.
Grinberg-Bleyer, Y., Baeyens, A., You,
S., Elhage, R., Fourcade, G., Gre-
goire, S., Cagnard, N., Carpentier,W.,
Tang, Q., Bluestone, J., Chatenoud,
L., Klatzmann, D., Salomon, B. L.,
and Piaggio, E. (2010). IL-2 reverses
established type 1 diabetes in NOD
mice by a local effect on pancreatic
regulatory T cells. J. Exp. Med. 207,
1871–1878.
Hamad, A. R. (2010). Analysis of gene
proﬁle, steady state proliferation and
apoptosis of double-negative T cells
in the periphery and gut epithelium
provides new insights into the bio-
logical functions of the Fas pathway.
Immunol. Res. 47, 134–142.
Harjutsalo,V., Forsblom,C., andGroop,
P. H. (2011). Time trends in mortal-
ity in patients with type 1 diabetes:
nationwide population based cohort
study. BMJ 343, d5364.
Henriques-Pons, A., and de Oliveira, G.
M. (2009). Is the Fas/Fas-L pathway a
promising target for treating inﬂam-
matory heart disease? J. Cardiovasc.
Pharmacol. 53, 94–99.
Herold, K. C., Gitelman, S. E., Masha-
rani, U., Hagopian, W., Bisikirska,
B., Donaldson, D., Rother, K., Dia-
mond, B., Harlan, D. M., and Blue-
stone, J. A. (2005). A single course
of anti-CD3 monoclonal antibody
hOKT3gamma1(Ala-Ala) results in
improvement in C-peptide responses
and clinical parameters for at least 2
years after onset of type 1 diabetes.
Diabetes 54, 1763–1769.
Hildeman, D. A., Zhu, Y., Mitchell, T.
C., Bouillet, P., Strasser, A., Kap-
pler, J., and Marrack, P. (2002).
Activated T cell death in vivo medi-
ated by proapoptotic bcl-2 fam-
ily member bim. Immunity 16,
759–767.
Hughes, P. D., Belz, G. T., Fortner, K. A.,
Budd, R. C., Strasser, A., and Bouillet,
P. (2008). Apoptosis regulators Fas
and Bim cooperate in shutdown of
chronic immune responses and pre-
vention of autoimmunity. Immunity
28, 197–205.
Hutcheson, J., Scatizzi, J. C., Siddiqui,
A. M., Haines, G. K. III, Wu, T.,
Li, Q. Z., Davis, L. S., Mohan, C.,
and Perlman, H. (2008). Combined
deﬁciency of proapoptotic regulators
Bim and Fas results in the early onset
of systemic autoimmunity. Immunity
28, 206–217.
Joslin, E. P. (1924). The treatment of
diabetes mellitus. Can. Med. Assoc. J.
14, 808–811.
Joslin, E. P. (1936). Insulin, old and new,
in the treatment of diabetes. Can.
Med. Assoc. J. 35, 526–531.
Ju, S., Panks, D., Cul, H., Ettin-
gor, R., Elkhatib, M., Sherr, D.,
Stanger, B., and Marshak-Rothstein,
A. (1995). Fas (CD95)/FasL interac-
tions required for programmed cell
death after T cell activation. Nature
373, 444–448.
Keymeulen, B., Walter, M., Mathieu, C.,
Kaufman, L., Gorus, F., Hilbrands,
R., Vandemeulebroucke, E., Van de
Velde, U., Crenier, L., De Block, C.,
Candon, S., Waldmann, H., Ziegler,
A. G., Chatenoud, L., and Pipeleers,
D. (2010). Four-year metabolic out-
come of a randomised controlled
CD3-antibody trial in recent-onset
type 1 diabetic patients depends
on their age and baseline resid-
ual beta cell mass. Diabetologia 53,
614–623.
Kim, Y. H., Kim, S., Kim, K. A., Yagita,
H., Kayagaki, N., Kim, K.W., and Lee,
M. S. (1999). Apoptosis of pancre-
atic beta-cells detected in accelerated
diabetes of NOD mice: no role of
Fas–Fas ligand interaction in autoim-
mune diabetes. Eur. J. Immunol. 29,
455–465.
Ko, G. J., Jang, H. R., Huang, Y., Womer,
K. L., Liu, M., Higbee, E., Xiao, Z.,
Yagita, H., Racusen, L., Hamad, A.
R., and Rabb, H. (2011). Blocking
Fas ligand on leukocytes attenuates
kidney ischemia-reperfusion injury.
J. Am. Soc. Nephrol. 22, 732–742.
Koreth, J., Matsuoka, K., Kim, H. T.,
McDonough, S. M., Bindra, B., Alyea,
E. P. III, Armand, P., Cutler, C., Ho,
V. T., Treister, N. S., Bienfang, D. C.,
Prasad, S., Tzachanis, D., Joyce, R. M.,
Avigan, D. E., Antin, J. H., Ritz, J.,
and Soiffer, R. J. (2011). Interleukin-2
and regulatory T cells in graft-versus-
host disease. N. Engl. J. Med. 365,
2055–2066.
Kotzin, B. L., Babcock, S. K., and
Herron, L. R. (1988). Deletion of
potentially self-reactive T cell recep-
tor speciﬁcities in L3T4-, Lyt-2- T
cells of lpr mice. J. Exp. Med. 168,
2221–2229.
Lenardo, M. J. (1996). Fas and the art
of lymphocyte maintenance. J. Exp.
Med. 183, 721.
Lohman, B. L., Razvi, E. S., and Welsh,
R. M. (1996). T-lymphocyte down-
regulation after acute viral infection
is not dependent on CD95 (Fas)
receptor-ligand interactions. J. Virol.
70, 8199–8203.
Maldonado, M. A., Kakkanaiah, V.,
MacDonald, G. C., Chen, F., Reap,
E. A., Balish, E., Farkas, W. R., Jen-
nette, J. C., Madaio, M. P., Kotzin,
B. L., Cohen, P. L., and Eisenberg,
R. A. (1999). The role of envi-
ronmental antigens in the sponta-
neous development of autoimmunity
in MRL-lpr mice. J. Immunol. 162,
6322–6330.
Marrack, P., and Kappler, J. (2004).
Control of T cell viability. Annu. Rev.
Immunol. 22, 765–787.
Miethke, T., Vabulas, R., Bittling-
maier, R., Heeg, K., and Wagner, H.
(1996). Mechanisms of peripheral T
cell deletion: anergized T cells are Fas
resistant but undergo proliferation-
associated apoptosis. Eur. J. Immunol.
26, 1459–1467.
Mogil, R. J., Radvanyi, L., Gonzalez-
Quintial, R., Miller, R., Mills, G.,
Theoﬁlopoulos, A. N., and Green, D.
R. (1995). Fas (CD95) participates in
peripheral T cell deletion and associ-
ated apoptosis in vivo. Int. Immunol.
7, 1451–1458.
Mohamood,A. S., Bargatze, D., Xiao, Z.,
Jie, C., Yagita, H., Ruben, D., Watson,
J., Chakravarti, S., Schneck, J. P., and
Hamad, A. R. (2008). Fas-mediated
apoptosis regulates the composition
of peripheral αβ T cell repertoire
by constitutively purging out dou-
ble negative T cells. PLoS ONE 3,
e3465. doi: 10.1371/journal.pone.
0003465
Mohamood,A. S., Guler, M. L., Xiao, Z.,
Zheng, D., Hess, A., Wang, Y., Yagita,
H., Schneck, J. P., and Hamad, A. R.
(2007). Protection fromautoimmune
diabetes and T-cell lymphoprolifera-
tion induced by FasL mutation are
differentially regulated and can be
uncoupled pharmacologically. Am. J.
Pathol. 171, 97–106.
Mountz, J. D., Smith, T. M., and Toth, K.
S. (1990). Altered expression of self-
reactive T cell receptorV beta regions
in autoimmune mice. J. Immunol.
144, 2159–2166.
Nagata, S., and Golstein, P. (1995).
The Fas death factor. Science 267,
1449–1456.
Nagata, S., and Suda, T. (1995). Fas
and Fas ligand: lpr and gldmutations.
Immunol. Today 16, 39–43.
Nakayama, M., Abiru, N., Moriyama,
H., Babaya, N., Liu, E., Miao, D.,
Yu, L., Wegmann, D. R., Hutton, J.
C., Elliott, J. F., and Eisenbarth, G.
S. (2005). Prime role for an insulin
epitope in the development of type 1
diabetes in NOD mice. Nature 435,
220–223.
Nakayama, M., Nagata, M., Yasuda,
H., Arisawa, K., Kotani, R., Yamada,
K., Chowdhury, S. A., Chakrabarty,
S., Jin, Z. Z., Yagita, H., Yokono,
K., and Kasuga, M. (2002). Fas/Fas
ligand interactions play an essen-
tial role in the initiation of murine
autoimmune diabetes. Diabetes 51,
1391–1397.
Patterson, C. C., Dahlquist, G. G., Gyu-
rus, E., Green, A., and Soltesz, G.
(2009). Incidence trends for child-
hood type 1 diabetes in Europe
during 1989–2003 and predicted
new cases 2005–20: a multicentre
prospective registration study. Lancet
373, 2027–2033.
Pescovitz, M. D., Greenbaum, C. J.,
Krause-Steinrauf, H., Becker, D. J.,
Gitelman, S. E., Goland, R., Got-
tlieb, P. A., Marks, J. B., McGee, P. F.,
Moran, A. M., Raskin, P., Rodriguez,
H., Schatz, D. A., Wherrett, D., Wil-
son,D.M., Lachin, J.M., and Skyler, J.
S. (2009). Rituximab, B-lymphocyte
depletion, and preservation of beta-
cell function. N. Engl. J. Med. 361,
2143–2152.
Petrovsky, N., Silva, D., Socha, L., Slat-
tery, R., and Charlton, B. (2002).
The role of Fas ligand in beta cell
destruction in autoimmune diabetes
of NOD mice. Ann. N. Y. Acad. Sci.
958, 204–208.
Saadoun, D., Rosenzwajg, M., Joly, F.,
Six, A., Carrat, F., Thibault, V., Sene,
D., Cacoub, P., and Klatzmann, D.
(2011). Regulatory T-cell responses
to low-dose interleukin-2 in HCV-
induced vasculitis. N. Engl. J. Med.
365, 2067–2077.
Sherry, N., Hagopian, W., Ludvigsson,
J., Jain, S. M., Wahlen, J., Ferry, R.
J. Jr., Bode, B., Aronoff, S., Hol-
land, C., Carlin, D., King, K. L.,
Wilder, R. L., Pillemer, S., Bonvini,
E., Johnson, S., Stein, K. E., Koenig,
S., Herold, K. C., and Daifotis, A.
G. (2011). Teplizumab for treatment
of type 1 diabetes (Protege study):
1-year results from a randomised,
placebo-controlled trial. Lancet 378,
487–497.
Siegel, R. M., Frederiksen, J. K.,
Zacharias, D. A., Chan, F. K., John-
son, M., Lynch, D., Tsien, R. Y., and
Lenardo, M. J. (2000). Fas preas-
sociation required for apoptosis sig-
naling and dominant inhibition by
pathogenic mutations. Science 288,
2354–2357.
Singer, P. A., Balderas, R. S., McEvilly,
R. J., Bobardt, M., and Theoﬁlopou-
los, A. N. (1989). Tolerance-related V
beta clonal deletions in normal CD4-
8-, TCR-alpha/beta+ and abnormal
lpr and gld cell populations. J. Exp.
Med. 170, 1869–1877.
Stranges, P. B., Watson, J., Cooper, C.
J., Choisy-Rossi, C. M., Stonebraker,
A. C., Beighton, R. A., Hartig, H.,
Sundberg, J. P., Servick, S., Kauf-
mann, G., Fink, P. J., and Chervonsky,
www.frontiersin.org July 2012 | Volume 3 | Article 196 | 7
“ﬁmmu-03-00196” — 2012/7/12 — 12:23 — page 8 — #8
Hamad et al. FasL: a counterintuitive immunotherapeutic target
A. V. (2007). Elimination of antigen-
presenting cells and autoreactive T
cells by fas contributes to preven-
tion of autoimmunity. Immunity 26,
629–641.
Strasser, A., Jost, P. J., and Nagata, S.
(2009). The many roles of FAS recep-
tor signaling in the immune system.
Immunity 30, 180–192.
Su, G., Blaine, S. A., Qiao, D., and Friedl,
A. (2007). Shedding of syndecan-1 by
stromal ﬁbroblasts stimulates human
breast cancer cell proliferation via
FGF2 activation. J. Biol. Chem. 282,
14906–14915.
Su, X., Hu, Q., Kristan, J. M., Costa,
C., Shen, Y., Gero, D., Matis, L.
A., and Wang, Y. (2000). Signiﬁcant
role for Fas in the pathogenesis of
autoimmune diabetes. J. Immunol.
164, 2523–2532.
Suzuki, I., Martin, S., Boursalian, T. E.,
Beers, C., and Fink, P. J. (2000). Fas
ligand costimulates the in vivo prolif-
eration of CD8+ T cells. J. Immunol.
165, 5537–5543.
Tang, Q., Adams, J. Y., Penaranda, C.,
Melli, K., Piaggio, E., Sgouroudis, E.,
Piccirillo, C. A., Salomon, B. L., and
Bluestone, J. A. (2008). Central role
of defective interleukin-2 production
in the triggering of islet autoimmune
destruction. Immunity 28, 687–697.
The Diabetes Control and Complica-
tions Trial Research Group. (1998).
Effect of intensive therapy on resid-
ual beta-cell function in patients
with type 1 diabetes in the diabetes
control and complications trial. A
randomized, controlled trial. The
Diabetes Control and Complications
Trial Research Group. Ann. Intern.
Med. 128, 517–523.
van Belle, T. L., Coppieters, K. T., and
von Herrath, M. G. (2011). Type 1
diabetes: etiology, immunology, and
therapeutic strategies. Physiol. Rev.
91, 79–118.
Waldner, H., Sobel, R. A., Howard,
E., and Kuchroo, V. K. (1997). Fas-
and FasL-deﬁcient mice are resis-
tant to induction of autoimmune
encephalomyelitis. J. Immunol. 159,
3100–3103.
Watanabe-Fukunaga, R., Brannan, C.,
Copeland, N., Jenkins, N., and
Nagata. S. (1992). Lymphoprolifer-
ation disorder in mice explained by
defects in Fas antigen that mediates
apoptosis. Nature 356, 314–317.
Weant, A. E., Michalek, R. D., Khan, I.
U., Holbrook, B. C., Willingham, M.
C., and Grayson, J. M. (2008). Apop-
tosis regulators Bim and Fas function
concurrently to control autoimmu-
nity and CD8+ T cell contraction.
Immunity 28, 218–230.
Wenzlau, J.M., Frisch, L.M.,Gardner, T.
J., Sarkar, S.,Hutton, J. C., andDavid-
son, H. W. (2009). Novel antigens in
type 1 diabetes: the importance of
ZnT8. Curr. Diab. Rep. 9, 105–112.
Yu, L., Herold, K., Krause-Steinrauf, H.,
McGee, P. L., Bundy, B., Pugliese,
A., Krischer, J., and Eisenbarth, G.
S. (2011). Rituximab selectively sup-
presses speciﬁc islet antibodies. Dia-
betes 60, 2560–2565.
Zhou, T., Bluethmann, H., Zhang, J.,
Edwards, C. K. III, and Mountz, J.
D. (1992). Defective maintenance of
T cell tolerance to a superantigen in
MRL-lpr/lpr mice. J. Exp. Med. 176,
1063–1072.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 10April 2012; accepted: 21 June
2012; published online: 12 July 2012.
Citation: Hamad ARAR, Arcara K,
Uddin S andDonnerT (2012)The poten-
tial of Fas ligand (apoptosis-inducing
molecule) as an unconventional thera-
peutic target in type 1 diabetes. Front.
Immun. 3:196. doi: 10.3389/ﬁmmu.
2012.00196
This article was submitted to Frontiers in
Immunological Tolerance, a specialty of
Frontiers in Immunology.
Copyright© 2012Hamad,Arcara, Uddin
and Donner. This is an open-access arti-
cle distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are cred-
ited and subject to any copyright notices
concerning any third-party graphics etc.
Frontiers in Immunology | Immunological Tolerance July 2012 | Volume 3 | Article 196 | 8
